https://www.cmaj.ca/content/cmaj/suppl/2018/05/29/190.22.E677.DC1/170453-guide-1-at.pdf
Hemant Shah MD MScCH HPTE , Marc Bilodeau MD, Kelly W. Burak MD MSc FRCPC , Curtis Cooper MD, Marina Klein MD MSc FRCPC, Alnoor Ramji MD FRCPC, Dan Smyth, MD, FRCPC, Jordan J. Feld MD MPH*
Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last publication of the Canadian Association for the Study of the Liver (CASL) consensus guidelines on the management of hepatitis C in 2015, major advances have occurred that warrant a review of recommended management approaches. Specifically, new direct-acting antiviral agents with improved rates of virologic clearance have been developed and approved for all genotypes in most specific patient populations. This 2018 update of the CASL guidelines on the management of hepatitis C reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches, and recommendations for the treatment of infected individuals with the newly approved antiviral agents, including those patients who have failed to respond to prior therapy, those with cirrhosis, and other specific co-morbidities. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.
